•
ER
ERNA
Ernexa Therapeutics Inc. Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
9.58M
Volume
102.66K
52W High
$11.07
52W Low
$1.08
Open
$1.22
Prev Close
$1.22
Day Range
1.15 - 1.22
About Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
Latest News
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
GlobeNewswire Inc.•May 10
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
GlobeNewswire Inc.•May 8
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
GlobeNewswire Inc.•Feb 20
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
GlobeNewswire Inc.•Jan 3
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
GlobeNewswire Inc.•Dec 20
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
GlobeNewswire Inc.•Dec 14
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
GlobeNewswire Inc.•Nov 1
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
GlobeNewswire Inc.•Sep 6